PerkinElmer licenses CHO cell line to Trinomab Biotech

By The Science Advisory Board staff writers

PerkinElmer has licensed its Horizon Discovery Chosource Chinese hamster ovary (CHO)-K1GS knockout cell line to Trinomab Biotech in China to produce a human monoclonal antibody drug candidate to fight tetanus toxin.

Trinomab was able to develop its drug candidate utilizing Horizon's Chosource cell line, including a gene-editing glutamine synthetase knockout CHO K1 cell line and well-established GS expression system. A phase I clinical trial in Australia is expected to be completed in August 2021.

More than nine biotherapeutics expressed in the Chosource cell line have progressed to investigational new drug filings, according to PerkinElmer.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?